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INTRODUCTION
● M. abscessus (MA) is a rapidly growing nontuberculous 
mycobacterium (NTM) found in water and soil which 
causes pulmonary, skin/soft tissue, and bone infections 
in children.1 
● This uncommon infection can be difficult to treat, 
requiring a combination of antibiotics for prolonged 
periods of time.1-5






● Vitals: Tmax 36.9
oC, HR 108, BP 115/78, RR 17, SpO2
100%
● Right lower extremity: medial tibial wound with 
bloody/cloudy drainage
● Intraoperative inspection: “Exudate diffusely around 
fracture and drainage had eroded through multiple spots 
in the closed incision.”
DIFFERENTIAL DIAGNOSIS
● Osteomyelitis, septic arthritis, cellulitis, fungal infections, 
NTM infection
TESTS
● Intraoperative aerobic/anaerobic cultures: No growth
● Intraoperative fungal cultures: No growth
● Intraoperative Acid-Fast Bacillus cultures: 
M. abscessus sub. bolletii positive for erm macrolide 
resistance gene:
† S: Susceptible; I: Intermediate; R: Resistant
‡ CLSI susceptibility break-points are unavailable for these agents; no interpretation of 
susceptibility can be given
FINAL DIAGNOSIS
● Osteomyelitis due to Mycobacterium abscessus sub. 
bolletii
TREATMENT
● Intravenous amikacin, cefoxitin, and linezolid x 6 months
● Developed evidence of nephrotoxicity and mild 
myelosuppression, discussed with MA experts 
● Given discussions, transitioned to indefinite course of 
oral linezolid + omadacycline + clofazimine
● MA is a challenging but uncommon cause of infection in 
immunocompetent patients.
● Additional research is needed to identify safe and 
efficacious antibiotic agents and regimens with activity 
against MA.
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DISCUSSION & REVIEW
● MA is an uncommon cause of osteomyelitis, associated 
with significant morbidity and poor prognosis.3
● MA infections require aggressive multidisciplinary 
management, often requiring multiple surgeries and 
combination antibiotic therapy.
● There is a paucity of data regarding treatment regimens 
and duration for MA infection.
● There are limited data to support compassionate, off-
label use of clofazimine for treatment of MA.
● Tigecycline has been used in salvage therapy for MA 
infections, but has an unfavorable side-effect profile.5,10
● Omadacycline is structurally similar to tigecycline (Fig 3), 
is better tolerated, and has shown promise in vitro 
against MA.● 15 year old previously healthy female with open fracture 
of tibia/fibula following ATV accident (Fig. 1)
● Surgically debrided, open reduction and internal fixation 
(Fig. 2)
● Completed 42-day course of piperacillin-tazobactam for 
polymicrobial infection at time of initial presentation.
● Cultures cleared, but patient had poor healing of wounds 
and persistently exuded pus despite antibiotics. 
● Returned to hospital 8 weeks after initial presentation
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Figure 1: Initial radiograph of patient’s 
severely comminuted fractures of the 
tibia and fibula 
Figure 2: Radiograph demonstrating 
near-anatomic re-alignment of tibia. 
Note presence of retained hardware
CASE DESCRIPTION
Figure 3: 
Comparative 
structures
